| Novo Nordisk has resources available just for you. |
View online |
|
|
|
 |
| NovoSeven® RT is used to treat bleeding episodes in people with hemophilia A or B with inhibitors, congenital Factor VII deficiency, Glanzmann’s thrombasthenia with resistance to platelets, and acquired hemophilia. |
|
|
|
 |
I feel like having hemophilia B is definitely more of a challenge than having hemophilia A. They have a lot more geared to them in this community as far as treatments and products. With an inhibitor, it makes it that much more different. |
|
| |
— Person with hemophilia B with inhibitors |
|
|
| You have more than just hemophilia B with inhibitors. You have support, a community, and a partner in Novo Nordisk. NovoSeven® RT has over 30 years of experience treating people with hemophilia B with inhibitors. |
|
|
|
| Selected Important Safety Information |
| What is the most important information I should know about NovoSeven® RT? |
| NovoSeven® RT may cause serious side effects, including: |
| • |
Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported |
|
| • |
Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function |
|
| • |
Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT |
|
| Please click here or scroll below for additional Important Safety Information. |
|
|
| Get support in your community |
| Connect with a Rare Blood Community Liaison (RBCL) to get personalized support, find local events, and learn more about NovoSeven® RT. |
|
|
|
|
|
|
| Here for you in all seasons. |
| Day to day and season to season, experience fast bleed control for even the most life-threatening bleeds with NovoSeven® RT.a |
| NovoSeven® RT is: |
|
 |
| In all bleeds in hemophilia A and B with inhibitorsb,c |
|
 |
| In all severe bleeding episodesd,e |
|
|
|
|
|
| aIn compassionate use situations including surgery, central nervous system hemorrhages, severe intra-abdominal bleeding, and other life-threatening bleeding episodes. |
| bProven effective in the adept™2 study, one of the largest clinical trials conducted in patients with hemophilia with inhibitors. The adept™2 study included people with hemophilia A with inhibitors (n=66) and people with hemophilia B with inhibitors (n=6). Of those who participated in the study, 57 were treated with NovoSeven® RT and 67 were treated with vatreptacog. |
| cAll bleeds refers to joint, target joint, skin, and mucous membrane, muscle, and other bleeding episodes (n=227 bleeding episodes). |
| dData shown from compassionate use program and 2 clinical studies including patients with hemophilia A or B with or without inhibitors and acquired hemophilia. |
| eA total of 518 severe bleeding episodes were studied. Bleeds included muscle, ENT (ear, nose, throat), CNS, joint and internal/retroperitoneal bleeds. |
|
|
| What is NovoSeven® RT? |
| NovoSeven® RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for: |
| • |
Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with a decreased or absent response to platelet transfusions |
|
| • |
Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia |
|
| Important Safety Information (cont’d) |
| • |
You should not use NovoSeven® RT if you have ever had allergic (hypersensitivity) reactions, including severe, whole body reactions (anaphylaxis) to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. Signs of allergic reaction include shortness of breath, rash, itching (pruritus), redness of the skin (erythema), or fainting/dizziness |
|
| What should I tell my healthcare provider before using NovoSeven® RT? |
| • |
Tell your healthcare provider if you have any of the following, as these may increase your risk of blood clots: |
| |
| ◦ |
congenital hemophilia and are also receiving treatment with aPCCs (activated prothrombin complex concentrates) |
| ◦ |
are an older patient particularly with acquired hemophilia and receiving other agents to stop bleeding |
| ◦ |
history of heart or blood vessel diseases |
|
| • |
Tell your healthcare provider and pharmacist about all the medicines you take, including all prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies |
|
| What are the possible side effects of NovoSeven® RT? |
| • |
The most common and serious side effects are blood clots |
|
| • |
Tell your healthcare provider about any side effects that bother you or do not go away, and seek medical help right away if you have signs of a blood clot or allergic reaction |
|
| Please click here for Prescribing Information. |
| NovoSeven® RT is a prescription medication. |
| You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. |
|
|
|
| PLEASE DO NOT RESPOND TO THIS EMAIL. If you would like to contact us, please click here or call 1‑877‑744‑2579. |
| UNSUBSCRIBE NOTICE |
| If you no longer want to receive communications from Novo Nordisk, click here to unsubscribe. You also may call us at 1-877-744-2579 or send us a letter that includes your full contact information (eg, name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see our Privacy Statement. |
|
NovoSeven® is a registered trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
© 2024 Novo Nordisk All rights reserved. US24NSVN00006 April 2024 |
 |
|
|
|
